Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.
Qian MeiWenying ZhangYang LiuQingming YangJohn E J RaskoJing NieJiejie LiuXiang LiLiang DongMeixia ChenYan ZhangLu ShiHuitao WuWeidong HanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Camrelizumab plus GVD chemotherapy offers a potent option as life-saving chemo-immunotherapy with promising efficacy and a manageable safety profile for patients with rrPMBCL, especially with bulky aggressive disease.
Keyphrases
- open label
- locally advanced
- phase ii study
- diffuse large b cell lymphoma
- rectal cancer
- squamous cell carcinoma
- cancer therapy
- phase ii
- lymph node
- clinical trial
- radiation therapy
- acute lymphoblastic leukemia
- phase iii
- acute myeloid leukemia
- multiple myeloma
- drug delivery
- photodynamic therapy
- study protocol
- hodgkin lymphoma
- ultrasound guided
- anti inflammatory
- randomized controlled trial
- combination therapy